MIR2054: A Drug Target / Disease Biomarker (G100302267)
MIR2054: A Drug Target / Disease Biomarker
MIR2054 is a drug target and a potential biomarker for various diseases, including cancer. MIR2054 is a small non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell signaling, gene regulation, and metabolism.
One of the most promising aspects of MIR2054 is its potential as a drug target. MIR2054 has been shown to interact with several protein molecules, including STAT3, NF-kappa-B, and MAPK/ERK. These interactions suggest that MIR2054 may be a useful target for drugs that target these signaling pathways.
MIR2054 has also been shown to play a role in cancer progression. In several studies, researchers have found that MIR2054 levels are elevated in various types of cancer, and that these levels are associated with poor prognosis. Additionally, MIR2054 has been shown to promote the growth and survival of cancer cells in cell culture and animal models.
Another potential application of MIR2054 is as a biomarker for certain diseases. For example, MIR2054 has been shown to be elevated in the blood samples of patients with heart disease, and has been associated with increased risk of cardiac events. Additionally, MIR2054 has been shown to be elevated in the urine samples of patients with diabetes, and has been associated with increased risk of complications.
In conclusion, MIR2054 is a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in these conditions and to develop safe and effective drugs that target MIR2054.
Protein Name: MicroRNA 2054
The "MIR2054 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR2054 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120
